Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers

Study Identifier:

CLI-06001AA1-14

ClinicalTrials.gov Identifier:

NCT06395610

EudraCT Identifier:

N/A

Study Contact Information:

N/A

Study Complete

Study Details

Medical Condition

Chronic Obstructive Pulmonary Disease

Study Drug

Drug: CHF6001 DPI
Drug: Erythromycin

Date

Mar 2024 - Jun 2024

Phase 1

Phase 2

Phase 3

Phase 4

N/A

Patient Requirements

Sex: Female & Male

Age: 18 - 55 Years

Requirements Information

Healthy Volunteers

Yes

Protocol Summary

The objective of this study is to investigate the effect of the interaction of Erythromycin (CYP3A4/5 moderate inhibitor) on the pharmacokinetic of CHF6001 (CYP3A4/5 substrate) in Healthy Volunteers.

Study Locations

Location

Status

Location

MC Comac Medical Ltd.

Sofia, Bulgaria, 1618

Status

N/A